MGNX
MacroGenics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.40
+3.53%Year over year
Reported trailing growth
- Revenue
- +2.3%
- EBITDA
- —
- EBIT
- +47.8%
- EPS
- +61.4%
- Free cash flow
- +12.1%
- Operating cash flow
- +11.6%
Forward estimates
Based on analyst estimates
- Revenue
- -49.0%
- EBITDA
- -11.3%
- EPS
- —
Three-year CAGR
- Revenue
- -0.1%
- EBITDA
- -3.9%
- EBIT
- +34.1%
- Net income
- -11.4%
- EPS
- -10.3%
- Free cash flow
- -15.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026